


## NEW APPROACH TO (3*R*, 4*R*)-3-AMINO-*N*-BENZYLOXYCARBONYL-4-HYDROXYHEXAHYDRO-1*H*-AZEPINE USING RING EXPANSION OF OPTICALLY ACTIVE PIPERIDINE DERIVATIVE

Toshiya Morie and Shiro Kato\*


Discovery Research Laboratories I, Dainippon Pharmaceutical Co., Ltd., Enoki  
33-94, Suita, Osaka 564, Japan

**Abstract**—New approach to (3*R*, 4*R*)-3-amino-*N*-benzyloxycarbonyl-4-hydroxyhexahydro-1*H*-azepine (**18**), which is the intermediate of the natural product balanol (**1**), is described. A key step in this method is ring expansion of the optically active piperidine derivative (**10**) to the corresponding hexahydro-1*H*-azepine (**12**) with retention of the configuration.

The (3*R*, 4*R*)-3-amino-4-hydroxyhexahydro-1*H*-azepine ring unit is a structural element found in the natural product balanol (**1**). Balanol (**1**) initially has been isolated as a metabolite produced by the fungus *Verticillium balanoides*<sup>1</sup> and more recently from species of *Fusarium mesismoides*<sup>2</sup> and markedly inhibits protein kinase C activity.<sup>3</sup> Due to its unique chemical structure, its biological activity, and its low availability from natural sources, the development of synthetic routes to balanol (**1**) or the derivatives of (3*R*, 4*R*)-3-amino-4-hydroxyhexahydro-1*H*-azepine (**2**) as logical precursors to **1** is of considerable interest. The optically active *N*-protected 3-amino-4-hydroxyhexahydro-1*H*-azepine has been prepared from D-serine,<sup>4</sup> D-isoascorbic acid,<sup>5</sup> (2*S*, 3*R*)-3-hydroxylysine,<sup>6</sup> or an acyclic chiral epoxy alcohol<sup>7</sup> obtained *via* Sharpless asymmetric epoxidation.<sup>8</sup> Moreover, syntheses of (±)-*trans*-3-amino-*N*-benzyl-4-hydroxyhexahydro-1*H*-azepine derivatives followed by the optical resolution of the racemate have been reported.<sup>9</sup>




We previously reported that 1-benzyl-2-(chloromethyl)piperidine (**3**) was treated with  $\text{NaN}_3$  in MeCN at refluxing temperature to form the reactive intermediate, the aziridinium cation (**4**) in solution, which could undergo ring expansion by  $\text{S}_{\text{N}}2$ -type attack of the azide anion at the methine carbon of the aziridinium ring to give 3-azido-1-benzylhexahydro-1*H*-azepine (**5**) along with the normal displacement product, the piperidine derivative (**6**), in good yield in 62 : 38 ratio (Scheme 1).<sup>10</sup> We expected that the reaction of




the chiral *N*-benzyl-2-(chloromethyl)-3-hydroxypiperidine with azide anion under the same conditions would afford the chiral 3-azido-*N*-benzyl-4-hydroxyhexahydro-1*H*-azepine as an expansion product, which is the important intermediate for the preparation of the (3*R*, 4*R*)-*N*-protected 3-amino-4-hydroxyhexahydro-1*H*-azepine. In this report, we describe a novel method for the preparation of (3*R*, 4*R*)-3-amino-*N*-benzyloxycarbonyl-4-hydroxyhexahydro-1*H*-azepine (**18**) based on ring expansion of the optically active 2-(methanesulfonyloxymethyl)piperidine derivative (**10**).

Our synthetic approach to **18** from the known compound (2*R*, 3*S*)-1-benzyl-3-methoxymethoxy-6-oxopiperidine-2-carboxylic acid ethyl ester<sup>11</sup> (**7**) is shown in Schemes 2 and 3. Reduction of the (2*R*, 3*S*)-6-oxopiperidine (**7**) with  $\text{BH}_3$  in THF at room temperature followed by treatment with 1% aqueous HCl at refluxing temperature gave a mixture of the desired piperidine (**8**) and the deprotected product, 1-benzyl-3-hydroxypiperidine-2-carboxylic ester<sup>12</sup> in *ca.* 2 : 1 ratio. The mixture was treated with chloromethyl methyl ether in the presence of Hünig base in  $\text{CHCl}_3$  to afford the 1-benzylpiperidine-2-carboxylic ester (**8**) in 88% overall yield. Reaction of the piperidine-2-carboxylic ester (**8**) with DIBAL-H in THF at 0 °C produced the 2-(hydroxymethyl)piperidine (**9**) in 89% yield. The ring expansion reaction was carried out according to our previously reported method.<sup>10</sup> Thus, **9** was treated with methanesulfonyl chloride in  $\text{CH}_2\text{Cl}_2$  in the presence of  $\text{Et}_3\text{N}$  at 5 °C to give the corresponding mesylate (**10**), which without further purification was allowed to react with  $\text{NaN}_3$  in MeCN at refluxing temperature for 2 h to afford a mixture of the desired ring expansion product, the 3-azido-1-benzylhexahydro-1*H*-azepine derivative (**12**) and the normal substituted piperidine (**13**) in 10 : 11 ratio.<sup>13</sup> The mixture was conveniently separated into the less polar hexahydro-1*H*-azepine **12** (31%) and the more polar piperidine **13** (34%) by medium-pressure column chromatography on silica gel. The structures of the diastereoisomerically pure compounds (**12**) and (**13**) were deduced using  $^1\text{H}$  NMR, IR, and MS spectra.<sup>14</sup> In the reaction of the piperidines (**3**) and (**10**) with  $\text{NaN}_3$ , there was a clear difference in ratio of the hexahydro-1*H*-azepines (**5**) and (**12**) vs the piperidines (**6**) and (**13**). This may be due to the difference between the substituents at the 3-position of the starting piperidines. In the *cis*-aziridinium intermediate (**11**), in particular, the attack at the methylene carbon (path *b*) would be preferred over path *a*

owing to steric hindrance at the 3-MOM group. Attempts to convert the (3*S*)-hydroxy group of several intermediate piperidines into the corresponding *R* forms using Mitsunobu inversion<sup>15</sup> were unsuccessful (Scheme 2).<sup>16</sup>



Reaction of the hexahydro-1*H*-azepine (**12**) thus prepared with benzyl chloroformate in toluene at room temperature proceeded smoothly to produce the carbamate (**14**) in 71% yield. After deprotection of the MOM group of **14** with 10% aqueous HCl, conversion of the resulting *cis* isomer (**15**) into the *trans* isomer (**17**) was carried out using Mitsunobu reaction; treatment of **15** with 4-nitrobenzoic acid, triphenylphosphine, and diisopropyl azodicarboxylate, followed by hydrolysis of the *trans* 4-nitrobenzoate derivative (**16**) by 2*N* NaOH gave the (3*R*, 4*R*)-3-azido-4-hydroxyhexahydro-1*H*-azepine (**17**) in 84% overall yield. Reduction of the azide group of the *trans* azido alcohol (**17**) with triphenylphosphine in aqueous THF at room temperature<sup>17</sup> gave the 3-amino-4-hydroxyhexahydro-1*H*-azepine (**18**), which was subsequently treated with 4-(benzyloxy)benzoyl chloride in  $\text{CH}_2\text{Cl}_2$  in the



presence of  $\text{Et}_3\text{N}$  at room temperature to afford the optically active 4-benzyloxy-*N*-(1-benzyloxycarbonyl-4-hydroxyhexahydro-1*H*-azepin-3-yl)benzamide (**19**) in 58% yield in 2 steps.<sup>18</sup> Spectroscopic data of **19** were identical with those prepared by different route<sup>4a</sup> (Scheme 3).

In conclusion, we have shown that the optically active 2-(methanesulfonyloxymethyl)piperidine (**10**) undergoes ring expansion with azide anion as a nucleophile to give the hexahydro-1*H*-azepine derivative (**12**) via the aziridinium cation (**11**). This ring expansion reaction was applied for the preparation of (3*R*, 4*R*)-3-amino-4-hydroxyhexahydro-1*H*-azepine derivative (**18**), which is the intermediate of balanol (**1**).

## REFERENCES AND NOTES

1. P. Kulanthaivel, Y. F. Hallock, C. Boros, S. M. Hamilton, W. P. Janzen, L. M. Ballas, C. R. Loomis, J. B. Jiang, B. Katz, J. R. Steiner, and J. Clardy, *J. Am. Chem. Soc.*, 1993, **115**, 6452.
2. S. Ohshima, M. Yanagisawa, A. Katoh, T. Fujii, T. Sano, S. Matsukuma, T. Furumai, M. Fujii, K. Watanabe, K. Yokose, M. Arisawa, and T. Okuda, *J. Antibiotics*, 1994, **47**, 639.
3. K. Koide, M. E. Bunnage, L. G. Paloma, J. R. Kanter, S. S. Taylor, L. L. Brunton, and K. C. Nicolaou, *Chem. Biol.*, 1995, **2**, 601.
4. a) K. C. Nicolaou, M. E. Bunnage, and K. Koide, *J. Am. Chem. Soc.*, 1994, **116**, 8402; b) K. C. Nicolaou, K. Koide, and M. E. Bunnage, *Chem. Eur. J.*, 1995, **1**, 454.
5. A. Tuch, M. Sanière, Y. Le Merrer, and J. Depezay, *Tetrahedron: Asymmetry*, 1996, **7**, 2901.
6. a) J. W. Lampe, P. F. Hughes, C. K. Briggers, S. H. Smith, and H. Hu, *J. Org. Chem.*, 1994, **59**, 5147; b) *idem, ibid.*, 1996, **61**, 4572.
7. D. Tanner, A. Almario, and T. Högberg, *Tetrahedron*, 1995, **51**, 6061.
8. Recently, two groups reported the synthesis of the (3*R*, 4*R*)-3-amino-4-hydroxyhexahydro-1*H*-azepine derivatives using the asymmetric epoxide ring opening reaction and the stannyl radical cyclization as key step; M. H. Wu and E. N. Jacobsen, *Tetrahedron Lett.*, 1997, **38**, 1693. T. Naito, M. Torieda, K. Tajiri, I. Ninomiya, and T. Kiguchi, *Chem. Pharm. Bull.*, 1996, **44**, 624; H. Miyabe, M. Torieda, T. Kiguchi, and T. Naito, *Synlett*, 1997, 580.
9. C. P. Adams, S. M. Fairway, C. J. Hardy, D. E. Hibbs, M. B. Hursthouse, A. D. Morley, B. W. Sharp, N. Vicker, and I. Warner, *J. Chem. Soc., Perkin Trans. 1*, 1995, 2355.
10. T. Morie, S. Kato, H. Harada, I. Fujiwara, K. Watanabe, and J. Matsumoto, *J. Chem. Soc., Perkin Trans. 1*, 1994, 2565.
11. N. Toyooka, Y. Yoshida, and T. Momose, *Tetrahedron Lett.*, 1995, **36**, 3715.
12. In the <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) spectrum, the signal for the hydroxy group at the 3-position appeared as a doublet centered at  $\delta$  2.83 with coupling constant of 7 Hz.
13. The ratio of **12** and **13** in the reaction mixture was determined by <sup>1</sup>H NMR spectrum.
14. **12**; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.52—2.21 (m, 4H), 2.52—2.83 (m, 4H), 3.42 (s, 3H, OCH<sub>3</sub>), 3.61 (m, 1H, 3-H), 3.65 and 3.73 (each d, each 1H,  $J = 14$  Hz, CH<sub>2</sub>Ph), 4.00 (ddd, 1H,  $J_{4\text{-H-5-H}} = 8, 3$  Hz,  $J_{4\text{-H-3-H}} = 3$  Hz, 4-H), 4.68 and 4.73 (each d, each 1H,  $J = 5$  Hz, OCH<sub>2</sub>O), 7.20—7.38 (m, 5H); MS  $m/z$ : 290 ( $M^+$ ), 248 ( $M^+ - N_3$ ); IR: 2095 ( $N_3$ )  $\text{cm}^{-1}$ . **13**; <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$ :

- 1.41—1.85 (m, 4H), 2.37—2.61 (m, 2H), 3.10 (ddd, 1H,  $J_{2-H-CH_2} = 7, 4$  Hz,  $J_{2-H-3-H} = 4$  Hz, 2-H), 3.38 (s, 3H, OCH<sub>3</sub>), 3.52 (dd, 1H,  $J_{CH_2-2-H} = 4$  Hz,  $J_{CH_2-CH_2} = 12$  Hz, CH<sub>2</sub>N<sub>3</sub>), 3.65 (dd, 1H,  $J_{CH_2-2-H} = 4$  Hz,  $J_{CH_2-CH_2} = 12$  Hz, CH<sub>2</sub>N<sub>3</sub>), 3.80 (s, 2H, CH<sub>2</sub>Ph), 3.89 (ddd, 1H,  $J_{3-H-4-H} = 4, 9$  Hz,  $J_{3-H-2-H} = 4$  Hz, 3-H), 4.66 and 4.71 (each d, each 1H,  $J = 5$  Hz, OCH<sub>2</sub>O), 7.20—7.40 (m, 5H); MS  $m/z$ : 290 (M<sup>+</sup>), 234 (M<sup>+</sup>-CH<sub>2</sub>N<sub>3</sub>); IR: 2095 (N<sub>3</sub>) cm<sup>-1</sup>.
15. O. Mitsunobu, *Synthesis*, **1981**, 1.
16. The corresponding tetrahydropyridine derivatives were isolated instead of the desired *trans* products.
17. a) N. Knouzi, M. Vaultier, L. Toupet, and R. Carrie, *Tetrahedron Lett.*, 1987, **28**, 1757; b) H. Takahashi, M. Kubota, S. Takahashi, and T. Momose, *Tetrahedron: Asymmetry*, 1996, **7**, 3047.
18. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>), MS, and IR (neat) spectral data of some selected compounds:  
 Compound (**8**): δ 1.30 (t, 3H,  $J = 7$  Hz, CH<sub>2</sub>CH<sub>3</sub>), 1.40—1.64 (m, 2H), 1.65—1.87 (m, 2H), 1.95 (m, 1H), 2.39 (td, 1H,  $J = 5, 7$  Hz), 2.91 (dt, 1H,  $J = 4, 10$  Hz), 3.35 (s, 3H, OCH<sub>3</sub>), 3.61 (d, 1H,  $J = 14$  Hz, CH<sub>2</sub>Ph), 3.70 (d, 1H,  $J = 14$  Hz, CH<sub>2</sub>Ph), 3.94 (ddd, 1H,  $J = 5, 10, 10$  Hz, 3-H), 4.21 (q, 2H,  $J = 7$  Hz, CH<sub>2</sub>CH<sub>3</sub>), 4.62 (d, 1H,  $J = 7$  Hz, OCH<sub>2</sub>O), 4.68 (d, 1H,  $J = 7$  Hz, OCH<sub>2</sub>O), 7.18—7.34 (m, 5H); MS  $m/z$ : 308 (MH<sup>+</sup>); IR: 1728 (CO) cm<sup>-1</sup>;  
 Compound (**9**): δ 1.55—1.80 (m, 4H), 2.34 (td, 1H,  $J = 5, 13$  Hz), 2.68 (ddd, 1H,  $J = 5, 10, 10$  Hz), 2.90 (ddd, 1H,  $J = 5, 7, 10$  Hz), 3.39 (s, 3H, OCH<sub>3</sub>), 3.74 (d, 1H,  $J = 13$  Hz, CH<sub>2</sub>Ph), 3.88 (d, 2H,  $J = 7$  Hz, CH<sub>2</sub>OH), 3.89 (d, 1H,  $J = 13$  Hz, CH<sub>2</sub>Ph), 4.01 (m, 1H, 3-H), 4.65 (d, 1H,  $J = 7$  Hz, OCH<sub>2</sub>O), 4.70 (d, 1H,  $J = 7$  Hz, OCH<sub>2</sub>O), 7.20—7.36 (m, 5H); MS  $m/z$ : 266 (MH<sup>+</sup>); IR: 3449 (OH) cm<sup>-1</sup>;  
 Compound (**14**): δ 1.46—2.15 (m, 4H), 3.19 (m, 1H), 3.36 (dd, 1H,  $J = 8, 14$  Hz), 3.42 (d, 3H,  $J = 2$  Hz, OCH<sub>3</sub>), 3.62—3.98 (m, 4H), 4.67 (d, 1H,  $J = 7$  Hz, OCH<sub>2</sub>O), 4.72 (d, 1H,  $J = 7$  Hz, OCH<sub>2</sub>O), 5.13 (d, 1H,  $J = 7$  Hz, CH<sub>2</sub>Ph), 5.14 (d, 1H,  $J = 7$  Hz, CH<sub>2</sub>Ph), 7.28—7.43 (m, 5H); MS  $m/z$ : 335 (MH<sup>+</sup>); IR: 2101 (N<sub>3</sub>), 1701 (CO) cm<sup>-1</sup>;  
 Compound (**16**): δ 1.60—2.13 (m, 3H), 2.99—3.35 (m, 2H), 3.50 (m, 1H), 3.67—4.18 (m, 4H), 5.18 (d, 1H,  $J = 4$  Hz, CH<sub>2</sub>Ph), 5.19 (d, 1H,  $J = 4$  Hz, CH<sub>2</sub>Ph), 7.30—7.42 (m, 4H), 8.15—8.43 (m, 5H); MS  $m/z$ : 440 (MH<sup>+</sup>); IR: 2108 (N<sub>3</sub>), 1716 (CO), 1528, 1350 (NO<sub>2</sub>) cm<sup>-1</sup>;  
 Compound (**17**): δ 1.47—1.74 (m, 2H), 1.75—2.07 (m, 2H), 2.13 (dd, 1H,  $J = 3, 7$  Hz), 3.00 (dd, 1H,  $J = 7, 14$  Hz), 3.15—3.55 (m, 3H), 3.70 (m, 1H), 3.96 (ddd, 1H,  $J = 3, 14, 24$  Hz), 5.16 (d, 1H,  $J = 7$  Hz, CH<sub>2</sub>Ph), 5.21 (d, 1H,  $J = 7$  Hz, CH<sub>2</sub>Ph), 7.30—7.45 (m, 5H); MS  $m/z$ : 291 (MH<sup>+</sup>); IR: 3420 (OH), 2108 (N<sub>3</sub>), 1682 (CO) cm<sup>-1</sup>.

Received, 25th November, 1997